Harvest One (TSXV: HVST) Investor Dashboard, page-121

Blackmores (ASX:BLK) does pretty well with nutrient supplements. As mentioned, it's just a categorisation to overcome regulatory roadblocks in the short term. MMJ has a long standing partnership with Yissum Research Development Company of the Hebrew University in Israel.

Gelpel and the upcoming Canigma device are more about the delivery system than the medicine. CBD/THC is available, but which method of consumption is most effective? Gelpel's trial results vs the market standard GW pharma's Sativiex was impressive.

The pill to combat pediatric epilipsy (based on gelpel tech) is in phase two of it's clinical trials. Part of the reason MMJ did the Harvest One deal was to essentially outsource raw materials production while retaining ownership, thus allowing MMJ's wholy owned subsidiary (Phytotech) to focus on R&D. A side bonus was exposure to receptive Canadian investors which raised more for awareness (and the kitty) than another capital raising on the ASX could ever have done. Bloody smart move in my book.

MMJ has been following a farm to pharma gameplan since day one, and so far I'm happy to see how thier vision has unfolded.